Sino Biopharmaceutical Limited

SEHK:1177 Stock Report

Market Cap: HK$57.2b

Sino Biopharmaceutical Future Growth

Future criteria checks 2/6

Sino Biopharmaceutical is forecast to grow earnings and revenue by 14.6% and 5.2% per annum respectively. EPS is expected to grow by 20.6% per annum. Return on equity is forecast to be 10.4% in 3 years.

Key information

14.8%

Earnings growth rate

20.6%

EPS growth rate

Pharmaceuticals earnings growth12.3%
Revenue growth rate5.8%
Future return on equity10.4%
Analyst coverage

Good

Last updated26 Mar 2024

Recent future growth updates

Recent updates

Sino Biopharmaceutical Limited's (HKG:1177) Intrinsic Value Is Potentially 34% Above Its Share Price

Mar 20
Sino Biopharmaceutical Limited's (HKG:1177) Intrinsic Value Is Potentially 34% Above Its Share Price

Sino Biopharmaceutical Limited's (HKG:1177) Shares May Have Run Too Fast Too Soon

Dec 18
Sino Biopharmaceutical Limited's (HKG:1177) Shares May Have Run Too Fast Too Soon

Does Sino Biopharmaceutical (HKG:1177) Have A Healthy Balance Sheet?

Dec 02
Does Sino Biopharmaceutical (HKG:1177) Have A Healthy Balance Sheet?

Sino Biopharmaceutical Limited (HKG:1177) Shares Could Be 41% Below Their Intrinsic Value Estimate

Nov 17
Sino Biopharmaceutical Limited (HKG:1177) Shares Could Be 41% Below Their Intrinsic Value Estimate

We Think Sino Biopharmaceutical (HKG:1177) Can Manage Its Debt With Ease

Aug 30
We Think Sino Biopharmaceutical (HKG:1177) Can Manage Its Debt With Ease

Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 50% Undervaluation?

May 26
Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 50% Undervaluation?

Sino Biopharmaceutical (HKG:1177) Has A Rock Solid Balance Sheet

Apr 20
Sino Biopharmaceutical (HKG:1177) Has A Rock Solid Balance Sheet

Is Sino Biopharmaceutical Limited (HKG:1177) Trading At A 38% Discount?

Feb 09
Is Sino Biopharmaceutical Limited (HKG:1177) Trading At A 38% Discount?

Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 41% Undervaluation?

Nov 11
Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 41% Undervaluation?

Sino Biopharmaceutical (HKG:1177) Seems To Use Debt Quite Sensibly

Oct 24
Sino Biopharmaceutical (HKG:1177) Seems To Use Debt Quite Sensibly

Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 46% Undervaluation?

Jul 08
Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 46% Undervaluation?

Is Sino Biopharmaceutical (HKG:1177) Using Too Much Debt?

Apr 28
Is Sino Biopharmaceutical (HKG:1177) Using Too Much Debt?

An Intrinsic Calculation For Sino Biopharmaceutical Limited (HKG:1177) Suggests It's 45% Undervalued

Jan 22
An Intrinsic Calculation For Sino Biopharmaceutical Limited (HKG:1177) Suggests It's 45% Undervalued

Sino Biopharmaceutical (HKG:1177) Has A Pretty Healthy Balance Sheet

Dec 03
Sino Biopharmaceutical (HKG:1177) Has A Pretty Healthy Balance Sheet

Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 41% Undervaluation?

Oct 19
Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 41% Undervaluation?

Sino Biopharmaceutical (HKG:1177) Has Re-Affirmed Its Dividend Of HK$0.02

Sep 03
Sino Biopharmaceutical (HKG:1177) Has Re-Affirmed Its Dividend Of HK$0.02

These 4 Measures Indicate That Sino Biopharmaceutical (HKG:1177) Is Using Debt Reasonably Well

Aug 27
These 4 Measures Indicate That Sino Biopharmaceutical (HKG:1177) Is Using Debt Reasonably Well

Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 38% Undervaluation?

Jul 14
Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 38% Undervaluation?

Sino Biopharmaceutical (HKG:1177) Seems To Use Debt Quite Sensibly

May 17
Sino Biopharmaceutical (HKG:1177) Seems To Use Debt Quite Sensibly

Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 31% Undervaluation?

Apr 01
Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 31% Undervaluation?

Earnings and Revenue Growth Forecasts

SEHK:1177 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202633,8713,4805,2824,6803
12/31/202536,2863,6765,2986,72720
12/31/202433,1973,3615,0576,33722
12/31/202330,2232,9494,7916,18622
6/30/202328,8641,8813,3144,987N/A
3/31/202328,8222,2124,0175,626N/A
12/31/202228,7802,5444,7196,265N/A
9/30/202228,2415,2964,8956,622N/A
6/30/202227,7018,0495,0716,980N/A
3/31/202227,21513,655N/AN/AN/A
12/31/202126,86114,6083,4995,366N/A
9/30/202126,12912,465N/AN/AN/A
6/30/202125,35310,0114,3376,105N/A
3/31/202124,6683,809N/AN/AN/A
12/31/202023,6472,7713,5375,325N/A
9/30/202023,0392,302N/AN/AN/A
6/30/202024,3542,5581,8273,373N/A
3/31/202024,2482,781N/AN/AN/A
12/31/201924,2342,7623,6225,325N/A
9/30/201924,4799,101N/AN/AN/A
6/30/201923,6919,1254,7746,543N/A
3/31/201922,4449,132N/AN/AN/A
12/31/201820,8899,0463,4175,094N/A
9/30/201819,1032,567N/AN/AN/A
6/30/201817,0622,4361,2312,572N/A
3/31/201815,6092,363N/AN/AN/A
12/31/201714,8192,1712,6243,733N/A
9/30/201714,4912,115N/AN/AN/A
6/30/201714,2581,8623,7044,773N/A
3/31/201713,8991,789N/AN/AN/A
12/31/201613,5431,637N/A2,995N/A
9/30/201613,2711,674N/AN/AN/A
6/30/201612,8581,604N/A1,757N/A
3/31/201612,5071,575N/AN/AN/A
12/31/201512,1891,490N/A1,919N/A
9/30/201512,0301,432N/AN/AN/A
6/30/201511,1241,447N/A1,973N/A
3/31/201510,5521,263N/AN/AN/A
12/31/20149,9001,210N/A1,840N/A
9/30/20149,2051,074N/AN/AN/A
6/30/20148,876951N/A2,000N/A
3/31/20148,434886N/AN/AN/A
12/31/20137,731809N/A1,230N/A
9/30/20138,069868N/AN/AN/A
6/30/20136,902815N/A1,292N/A
3/31/20136,405762N/AN/AN/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 1177's forecast earnings growth (14.6% per year) is above the savings rate (2%).

Earnings vs Market: 1177's earnings (14.6% per year) are forecast to grow faster than the Hong Kong market (12.7% per year).

High Growth Earnings: 1177's earnings are forecast to grow, but not significantly.

Revenue vs Market: 1177's revenue (5.2% per year) is forecast to grow slower than the Hong Kong market (8% per year).

High Growth Revenue: 1177's revenue (5.2% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 1177's Return on Equity is forecast to be low in 3 years time (10.4%).


Discover growth companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.